Acquiring Company
Rubicon Research Limited
Acquired Company
Alkem Laboratories
ThaneMumbaiManufacturingBiotechnologyPharmaceuticalManufacturingBiotechnologyPharmaceuticalDescription
Rubicon Research Limited has successfully acquired Alkem Laboratories' formulations manufacturing facility in Pithampur for Rs. 149 crores. This acquisition enhances Rubicon's manufacturing capabilities and supports its strategy to expand in the US market. The facility, which was US FDA inspected in 2022, positions Rubicon for future growth in high-potency products and strengthens its supply chain.
Quick answer
Rubicon Research Limited is acquiring Alkem Laboratories, announced June 24, 2025. Rubicon Research Limited is based in Thane, Maharashtra, India.
- How much did Rubicon Research Limited pay for Alkem Laboratories?
- The deal value was not disclosed.
- What does Rubicon Research Limited do?
- Rubicon Research Limited is a pharmaceutical formulations company with an expanding portfolio of specialty and drug-device combination products.
- Where are Rubicon Research Limited and Alkem Laboratories based?
- Rubicon Research Limited is based in Thane, Maharashtra, India. Alkem Laboratories is based in Mumbai, Maharashtra, India.
- Who are the decision-makers at Rubicon Research Limited?
- Fundz holds 2 contacts at Rubicon Research Limited. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Cerevel Therapeutics for $45 per share (May 28, 2025)
- ESTEVE acquires Regis Technologies for U.S. expansion (July 31, 2025)
- Esteve Pharmaceuticals acquires Caprelsa® from Sanofi (July 1, 2025)
- Intas acquires Accord BioPharma to enhance supply (August 7, 2025)
- AbbVie to acquire Capstan Therapeutics (July 15, 2025)
- AbbVie to acquire Capstan Therapeutics for $2.1B, $2.1B (June 30, 2025)
Who to call at Rubicon Research Limited, and when
When Rubicon Research Limited changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Rubicon Research Limited raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Rubicon Research Limited, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Rubicon Research Limited. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Rubicon Research Limited makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Alkem Laboratories?
Alkem Laboratories was acquired by Rubicon Research Limited, based in Thane. The deal was reported on June 24, 2025. Rubicon Research Limited is a pharmaceutical formulations company with an expanding portfolio of specialty and drug-device combination products. Rubicon Research Limited is privately held and operates in Manufacturing.
When did Rubicon Research Limited acquire Alkem Laboratories?
Rubicon Research Limited's acquisition of Alkem Laboratories was reported on June 24, 2025. Rubicon Research Limited has successfully acquired Alkem Laboratories' formulations manufacturing facility in Pithampur for Rs. 149 crores. This acquisition enhances Rubicon's manufacturing capabilities and supports its strategy to expand in the US market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Alkem Laboratories do?
Alkem Laboratories Ltd. is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1973, it has become a significant player in both the Indian and global pharmaceutical markets. It is privately held, operating in Manufacturing, and is based in Mumbai.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.